8-K: Merit Medical to Acquire Cook Medical's Lead Management Portfolio for $210 Million, Updates 2024 Guidance

Merit Medical Systems, Inc. has agreed to acquire Cook Medical's lead management portfolio for approximately $210 million, expecting the deal to close in the fourth quarter of 2024 and updating its full-year 2024 financial guidance.

Summary

• Merit Medical Systems has entered into an agreement to purchase Cook Medical's lead management portfolio for about $210 million in cash.
• The acquisition is expected to close in the fourth quarter of 2024, pending regulatory approvals and other closing conditions.
• Merit plans to fund the acquisition using a combination of cash on hand and borrowings from its long-term credit facility.
• Cook Medical will provide manufacturing and other services to Merit for a two-year transition period.
• The acquired assets generated approximately $37 million in revenue in 2023, with 41% from the US, 42% from EMEA, 11% from APAC, and 6% from other regions.
• The acquisition is projected to add $4 to $6 million in revenue for Merit in the last two months of 2024, from a projected closing date of October 31, 2024.
• Merit has updated its full-year 2024 revenue guidance to $1.339 $1.351 billion, and non-GAAP earnings per share to $3.25 $3.34.
• The acquisition is expected to be modestly dilutive to 2024 non-GAAP profitability but accretive to non-GAAP gross margin in the first full year post-close, and accretive to non-GAAP net income and earnings per share in the second full year post-close.
• Merit also announced positive results from its WRAPSODY WAVE trial, showing 89.8% target lesion primary patency at 6 months compared to 62.8% for standard angioplasty.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strategic acquisition, positive clinical trial results, and updated financial guidance. While there are some dilutive effects in the short term, the long-term outlook is positive.

Positives

• The acquisition of Cook Medical's lead management portfolio is expected to strengthen Merit's electrophysiology and CRM business.
• The acquired assets have a solid growth profile in an underpenetrated global market.
• The acquisition is projected to be accretive to non-GAAP gross margin in the first full year post-close.
• The WRAPSODY WAVE trial demonstrated superior patency rates compared to standard angioplasty, potentially establishing a new standard of care.
• Merit reaffirmed its full-year 2024 financial guidance previously issued on August 1, 2024.

Negatives

• The acquisition is expected to be modestly dilutive to Merit's full-year 2024 non-GAAP profitability.
• The acquisition is projected to be dilutive to Merit's full-year 2024 GAAP net income and GAAP earnings per share.
• The acquisition is projected to be dilutive to Merit's GAAP net income and GAAP earnings per share in the first full-year post close.

Risks

• The closing of the acquisition is subject to regulatory approvals, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
• There is no guarantee that the acquisition will be completed.
• The integration of the acquired assets and operations may present challenges.
• The company's financial guidance is subject to risks and uncertainties, including material acquisitions, non-recurring transactions, or other factors beyond Merit's current expectations.
• The WRAPSODY device is not yet approved for commercial distribution in the United States.

Future Outlook

Merit expects the acquisition to strengthen its position in the cardiac intervention market and to be accretive to non-GAAP earnings per share in the second full year post-close. The company has updated its full-year 2024 financial guidance to include the projected impact of the acquisition.

Management Comments

• Fred P. Lampropoulos, Merit's Chairman and CEO, stated that the acquisition is consistent with their Continued Growth Initiatives and will strengthen their electrophysiology and CRM business.
• Mr. Lampropoulos also mentioned that the transaction will enhance their position in the cardiac intervention market, which they estimate represents an annual addressable opportunity of more than $900 million in the US, EMEA and APAC regions.
• Mr. Lampropoulos noted that the company has updated its full-year 2024 financial guidance to include the projected impact of the acquisition from a prospective closing date of October 31, 2024 to December 31, 2024.
• Mahmood K. Razavi, MD, FSIR, FSVM, stated that WRAPSODY should be the new standard of care for patients requiring AV fistula maintenance.
• Robert G. Jones, FRCR, stated that the potential for WRAPSODY to help safely extend vascular access for patients is a vital component of care.

Industry Context

This acquisition aligns with the trend of consolidation in the medical device industry, as companies seek to expand their product portfolios and market reach. Merit's move to acquire Cook Medical's lead management portfolio is a strategic step to enhance its position in the growing cardiac intervention market.

Comparison to Industry Standards

• The lead management market is dominated by a few large players such as Medtronic, Abbott, and Boston Scientific. Merit's acquisition of Cook Medical's portfolio positions them to compete more effectively in this space.
• The WRAPSODY trial results, with 89.8% patency at 6 months, significantly exceed the typical patency rates achieved with standard angioplasty, which are often in the range of 50-70% at 6 months. This suggests a potential for WRAPSODY to become a leading product in the vascular access market.
• The acquisition is similar to other strategic acquisitions in the medical device industry where companies acquire complementary product lines to expand their market presence and revenue streams. For example, Medtronic's acquisition of Covidien and Abbott's acquisition of St. Jude Medical are comparable in terms of strategic intent.

Stakeholder Impact

• Shareholders may see a positive impact from the acquisition and potential for long-term growth.
• Employees of both Merit and the acquired Cook Medical business may experience changes during the transition period.
• Customers will have access to a more comprehensive product portfolio.
• Suppliers may see changes in their relationships with Merit.
• Creditors may be impacted by the increased debt from the acquisition.

Next Steps

• Merit will work to obtain regulatory approvals for the acquisition.
• Merit will integrate the acquired assets and operations.
• Merit will continue to pursue regulatory approval for the WRAPSODY device in the United States.
• Merit will discuss the acquisition and updated outlook for 2024 on its third quarter earnings report on October 30, 2024.

Key Dates

Keywords

acquisition, lead management, medical devices, electrophysiology, cardiac rhythm management, WRAPSODY, patency, financial guidance, Merit Medical, Cook Medical